Senior associate Timothy Slattery (Washington, D.C.-Antitrust) has authored the article “Sample Shaming: FDA’s Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry” in Antitrust Advisors, a publication of the American Health Lawyers Association Antitrust Practice Group. The article was published in September 2018.

Read Sample Shaming: FDA’s Open Letter on Access to Samples Under REMS Programs Publically Calls Out Branded Drug Manufacturers to Aid Generic Entry